Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Karl Ernst Siegler"'
Publikováno v:
Clinical Pharmacology in Drug Development. 3:290-296
The pharmacokinetics of teneligliptin was compared in 3 groups of 8 subjects assigned according to their degree of hepatic impairment (mild, moderate, or matched healthy subjects). Hepatic impairment was associated with an increase in maximal plasma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b64a23b0acc6943058c41ae3e14856fd
https://doi.org/10.1002/cpdd.89
https://doi.org/10.1002/cpdd.89
Publikováno v:
Clinical Pharmacology in Drug Development. 2:246-254
The pharmacokinetics of teneligliptin was compared in renally impaired and healthy subjects. Subjects were assigned to one of four groups of eight subjects, according to the stage of disease [mild, moderate, severe or end stage renal disease (ESRD)],
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54d4fbfa2b6489ac5a5d0ef1ceea29b5
https://doi.org/10.1002/cpdd.29
https://doi.org/10.1002/cpdd.29
Autor:
Laura Rabinovich-Guilatt, Asa Rembratt, Atef Halabi, Ofer Spiegelstein, Armin Schultz, Karl Ernst Siegler
Publikováno v:
British Journal of Clinical Pharmacology
Aim Pridopidine, a new oral drug for treatment of patients with motor symptoms associated with Huntington's Disease (HD) is currently under development. In steady-state conditions, pridopidine elimination is mediated primarily through renal excretion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9041d19f08a26056f8e632b019857613
https://pubmed.ncbi.nlm.nih.gov/26407011
https://pubmed.ncbi.nlm.nih.gov/26407011
Publikováno v:
Herz. 29:651-655
Der Einsatz von Glykoprotein-(GP-)IIb/IIIa-Inhibitoren hat in randomisierten Studien zu einer Verringerung der Rate ischamischer Komplikationen bei Patienten mit perkutaner koronarer Intervention (PCI) gefuhrt. Im vorliegenden prospektiven Register s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::699e335f39663206329a15b372182709
https://doi.org/10.1007/s00059-004-2565-5
https://doi.org/10.1007/s00059-004-2565-5
Publikováno v:
Clinical pharmacology in drug development. 3(4)
The pharmacokinetics of teneligliptin was compared in 3 groups of 8 subjects assigned according to their degree of hepatic impairment (mild, moderate, or matched healthy subjects). Hepatic impairment was associated with an increase in maximal plasma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::58a77fd01ac5a3f305f89c0b7ef56721
https://pubmed.ncbi.nlm.nih.gov/27128835
https://pubmed.ncbi.nlm.nih.gov/27128835
Autor:
Atef, Halabi, Haidar, Maatouk, Karl Ernst, Siegler, Nadja, Faisst, Volkmar, Lufft, Norbert, Klause
Publikováno v:
Clinical pharmacology in drug development. 2(3)
The pharmacokinetics of teneligliptin was compared in renally impaired and healthy subjects. Subjects were assigned to one of four groups of eight subjects, according to the stage of disease [mild, moderate, severe or end stage renal disease (ESRD)],
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::27f8c8cba86540c45bda7f513c40efb0
https://pubmed.ncbi.nlm.nih.gov/27121786
https://pubmed.ncbi.nlm.nih.gov/27121786
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 23(1)
Filgrastim XM02 is a biosimilar non-glycosylated recombinant methionyl form of human granulocyte colony-stimulating factor (r-MetHuG-CSF) expressed in Escherichia coli for subcutaneous and intravenous administration in the treatment of different form
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::badb37d21212e88bb96a4176dea2824f
https://pubmed.ncbi.nlm.nih.gov/19344191
https://pubmed.ncbi.nlm.nih.gov/19344191
Publikováno v:
Herz. 29(7)
The use of potent platelet inhibitors has been shown to reduce the rate of ischemic complications in patients with percutaneous coronary intervention (PCI) in randomized clinical trials. Eptifibatide is a small-molecule glycoprotein (GP) IIb/IIIa rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5f71102c923bfe414cf538ae8a8a9121
https://pubmed.ncbi.nlm.nih.gov/15580317
https://pubmed.ncbi.nlm.nih.gov/15580317
Autor:
Jörg Rustige, Karlheinz Seidl, Ralf Zahn, Birgit Frilling, Klaus Dönges, Boris Fraiture, Torsten Becker, Jochen Senges, Karl Ernst Siegler, Bernd Mark
Publikováno v:
The American journal of cardiology. 89(4)
Risk factors for bleeding were found in varying rates in both groups of patients. Neither adjunctive heparin therapy nor risk factors for bleeding complications could sufficiently explain the significantly higher rates of peri-interventional bleeding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cc04ea9d9acb8711e90a34ec8a439e0
https://pubmed.ncbi.nlm.nih.gov/11835927
https://pubmed.ncbi.nlm.nih.gov/11835927
Autor:
Uwe Zeymer, Rudolf Schiele, Ricardo Seabra-Gomes, Anselm K. Gitt, Paolo M. Fioretti, Karl Ernst Siegler, David Hashdai, Jochen Senges, Jean-Pierre Bassand, Keith D. Dawkins, Martin Gottwik
Publikováno v:
Journal of the American College of Cardiology. 41:323
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::283e4130c7bdb85270938f942209c446
https://doi.org/10.1016/s0735-1097(03)81970-8
https://doi.org/10.1016/s0735-1097(03)81970-8